{
    "clinical_study": {
        "@rank": "83823", 
        "arm_group": {
            "arm_group_label": "estradiol / norethisterone acetate", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study is conducted in Europe. The aim of this study is to investigate the bleeding\n      profile after switch from Trisekvens\u00ae to Activelle\u00ae (1.0 mg estradiol / 0.5 mg\n      norethisterone acetate (NETA))."
        }, 
        "brief_title": "Bleeding Profile With Continuous Hormone Replacement Therapy of Activelle\u00ae in Postmenopausal Women", 
        "completion_date": {
            "#text": "June 2003", 
            "@type": "Actual"
        }, 
        "condition": [
            "Menopause", 
            "Healthy"
        ], 
        "condition_browse": {
            "mesh_term": "Hemorrhage"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy women\n\n          -  At least 3 months on Trisekvens\u00ae before screening period\n\n          -  Ability to understand and comply with the protocol requirements\n\n        Exclusion Criteria:\n\n          -  Less than 12 months or more than 36 months postmenopausal judged by the Investigator\n\n          -  Known, suspected, or past history of hormone dependent tumor/cancers\n\n          -  Deep venous thrombosis, active thrombophlebitis, thromboembolic disorders,\n             cerebrovascular accidents or past history of these conditions\n\n          -  Ischemic heart disease or myocardial infarction within 6 months prior to\n             randomization"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "191", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01705249", 
            "org_study_id": "KLIM-1408"
        }, 
        "intervention": {
            "arm_group_label": "estradiol / norethisterone acetate", 
            "description": "After a screening period of 12 weeks (three lunar months) in which the subjects still are on Trisekvens\u00ae followed by a treatment period of 24 weeks (six lunar months) in which the subjects are treated with Activelle\u00ae.", 
            "intervention_name": "1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Estradiol", 
                "Polyestradiol phosphate", 
                "Estradiol valerate", 
                "Estradiol 3-benzoate", 
                "Estradiol 17 beta-cypionate", 
                "Norethindrone", 
                "Norethindrone acetate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 11, 2012", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Oslo", 
                        "country": "Norway", 
                        "zip": "0309"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "S\u00f6dert\u00e4lje", 
                        "country": "Sweden", 
                        "zip": "151 23"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Norway", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Bleeding Profile With Continuous Hormone Replacement Therapy in Postmenopausal Women: A Prospective, Open, Multicenter Trial of Activelle\u00ae Treatment Following Switch From Trisekvens\u00ae", 
        "overall_official": {
            "affiliation": "Novo Nordisk Scandinavia AB", 
            "last_name": "Egil Wickstr\u00f8m", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Norway: Norwegian Medicines Agency", 
                "Sweden: Medical Products Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Postmenopausal women's acceptance of bleeding", 
            "safety_issue": "No", 
            "time_frame": "After 24 weeks of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01705249"
        }, 
        "responsible_party": {
            "name_title": "Public Access to Clinical Trials", 
            "organization": "Novo Nordisk A/S"
        }, 
        "secondary_outcome": [
            {
                "measure": "Bleeding profile in postmenopausal women", 
                "safety_issue": "No", 
                "time_frame": "After 24 weeks of treatment"
            }, 
            {
                "measure": "Acceptance of hot flushes and breast tenderness", 
                "safety_issue": "No", 
                "time_frame": "After 24 weeks of treatment"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2001", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}